Escitalopram and Deutetrabenazine: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Escitalopram
Deutetrabenazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of QT interval prolongation and increased CYP2D6 substrate exposure
Interaction Deep Dive
Escitalopram may prolong the QT interval and coadministration with another QT interval-prolonging drug may result in additive QT interval prolongation. Also, concomitant use of escitalopram (a CYP2D6 inhibitor) with CYP2D6 substrates may increase the substrate concentrations and the risk of adverse reactions of these substrates. Exercise caution during coadministration of escitalopram and drugs metabolized by CYP2D61.
Why it happens (mechanism)
Additive QT interval prolongation; inhibition of CYP2D6 substrate metabolism by escitalopram
Literature reports
2 reports — tap to read
a) In a retrospective study of premenopausal women diagnosed with stage I to III breast cancer in the Predictors of Breast Cancer Recurrence (ProBe CaRe) cohort (N=4493) using Bayesian joint modeling, patients concomitantly taking tamoxifen with a CYP2D6 inhibitor, including escitalopram, for more than half of the intended tamoxifen-treatment time had a higher recurrence rate of breast cancer compared with patients not taking a CYP2D6 inhibitor with tamoxifen (HR, 1.24; 95% CI, 0.96 to 1.58). This association was stronger with strong CYP2D6 inhibitors (HR, 1.25; 95% CI, 0.88 to 1.73) compared with weak CYP2D6 inhibitors (HR, 1.15; 95% CI, 0.57 to 1.53) 2. Plasma concentrations of 4-hydroxy-N-desmethyl tamoxifen (endoxifen), the active metabolite of tamoxifen, are highly dependent on the CYP2D6 metabolic pathway. Studies have shown that concomitant use of tamoxifen and paroxetine, another CYP2D6 inhibitor, has resulted in reduced plasma concentrations of endoxifen 3.
b) Administration of a single dose of desipramine 50 mg, a CYP2D6 substrate, to subjects treated with a 21-day regimen of escitalopram 20 mg/day resulted in desipramine Cmax and AUC elevations of 40% and 100%, respectively 1.
Common questions
Can I take Escitalopram and Deutetrabenazine together?
An increased risk of QT interval prolongation and increased CYP2D6 substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Escitalopram and Deutetrabenazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Escitalopram or Deutetrabenazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: LEXAPRO(R) oral tablets, oral solution, escitalopram oral tablets, oral solution. Abbvie, Inc (per FDA), North Chicago, IL, 2023. DailyMed
- Woolpert KM, Cronin-Fenton DP, Damkier P, et al: Drug interactions with tamoxifen and treatment effectiveness in premenopausal breast cancer patients: a Bayesian joint modeling approach. Pharmacoepidemiol Drug Saf 2025; 34(5):e70157-. PubMed
- Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85(2):151-159. DOI
Keep reading about Escitalopram
Keep reading about Deutetrabenazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist